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ABSTRACT
Objective: The aim of this study is to analyze the prognostic role of lymph-vascular space 
invasion (LVSI), evaluated in a semi-quantitative fashion on prognosis of early stage, low risk 
endometrial cancer (EC).
Methods: We enrolled patients who underwent surgery for endometrial cancer between 
2003 and 2018 in two referral cancer center. All patients had endometrioid EC, G1–G2, with 
myometrial invasion <50%, and no lymph-node involvement. LVSI was analyzed in a semi-
quantitative way, according to a 3-tiered scoring system in absent, focal and substantial.
Results: Among 524 patients, any positive LVSI was found in 57 patients (10.9%) with focal 
LVSI (n=35, 6.7%) and substantial LVSI (n=22, 4.2%). Substantial LVSI was associated to 
higher rate of G2 (p<0.001), myometrial infiltration (p=0.002) and greater tumor dimensions 
(p=0.014). Patients with substantial LVSI were more likely to receive adjuvant treatment 
(6.6% vs. 52.6%, p<0.001). The 5-year OS was 99.5% in patients with absent LVSI and 70.6% 
in those with substantial LVSI (p<0.001). The 5-year disease free survival (DFS) was 93.6% 
in patients with absent LVSI and 56.5% in those with substantial LVSI (p<0.001). The rate of 
distant failures increased from 1.8% for absent LVSI to 22.7% for substantial LVSI (p=0.002). 
In univariate analysis substantial LVSI was the strongest predictor of poor overall survival 
(hazard ratio [HR]=11.9, p=0.001). Multivariate analysis showed that substantial LVSI was 
an independent predictive factor of both recurrence (HR=5.88, p=0.001) and distant failure 
(HR=10.6, p=0.006).
Conclusions: Substantial LVSI represents the strongest independent risk factor for decreased 
survival and distant relapse, indicating a role for potential hematogenous dissemination.
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INTRODUCTION
Lymph-vascular space invasion (LVSI) is a pathologic finding defined by the presence of 
tumor cells within lymphatic vessels and/or small capillaries, outside the main tumor. It has 
been found in up to 35% of endometrial cancer (EC) and in about 10%–15% of International 
Federation of Gynaecology and Obstetrics (FIGO) stage I EC, and its presence is frequently 
associated to other uterine risk factors such as high grade and deep myometrial infiltration 
(MI). Several studies confirmed the role of LVSI as independent predictor of poor prognosis 
in patients with FIGO stage I–III EC [1]. In particular, the presence of LVSI has been 
associated with a detrimental effect on both disease free survival (DFS) and overall survival 
(OS), and a higher rate of distant recurrences and lymph node (LN) metastasis. However, 
even in patients with negative LNs the presence of LVSI was associated to decreased survival, 
suggesting a role for the hematogenous dissemination. In the 2016, European Society for 
Medical Oncology-European Society of Gynaecological Oncology-European Society for 
Radiotherapy and Oncology Consensus guidelines introduced patients with low-risk features, 
positive LVSI and incomplete surgical staging in the high-intermediate risk class, suggesting 
the consideration of adjuvant treatment in those patients [2].
At this point there are 2 rising issues to be addressed: 1) it is well known that LVSI is associated 
to poor prognosis and higher risk of nodal metastasis. However, there are few studies in 
literature analyzing if the same effect of LVSI on survival is present even in lymph-node negative 
patients and more specifically in patients with low-risk pathologic features (i.e., superficial 
myometrial invasion and well-moderately differentiated grading). The clinical relevance of this 
issue become even more important because we are focusing on a subgroup of patients that less 
frequently undergo adjuvant treatment. 2) LVSI is often described in a qualitative dichotomized 
manner as present or absent. Due to the absence of well-defined pathologic criteria to classify 
LVSI in a quantitative way, there is not a consensus on this definition. However, some studies 
in literature tried to build a scoring system based on a quantitative analysis of the number of 
vessels involved [3]. Hachisuga et al. [3] classified LVSI in 3 degrees differentiating the absence, 
the presence of a focus around the tumor, or the presence of diffuse and multifocal LVSI around 
the tumor or in the myometrium. A sub-analysis of PORTEC1 and 2 study underlined the 
relevance of this semi-quantitative scoring system demonstrating the role of substantial LVSI in 
contrast to focal or absent LVSI on survival and distant metastasis [4].
The aim of this study was to evaluate the prognostic impact of a three-tiered scoring system 
of LVSI in patients with EC and low risk pathologic features. The originality of our study relies 
in the analysis of a very selected population, in order to catch purely the effect of LVSI on 
prognosis in patients with no other risk factors and leaving a qualitative classification in favor 
of a quantitative evaluation of LVSI.
MATERIALS AND METHODS
We retrospectively analyzed patients undergoing surgery for early-stage endometrial cancer 
at Fondazione Policlinico Universitario A. Gemelli, IRCCS in Roma between 2003 and 2018, 
and at A.R.N.A.S. Ospedale civico di Cristina Benfratelli in Palermo between 2016 and 
2018. All patients gave their written consent to the use of clinical data for research purposes 
and the study was approved by the Institutional Review Board. We included in the analysis 
patients with endometrioid histology, well-moderately differentiated (G1–G2), superficially 
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infiltrating (<50% myometrial invasion) endometrial cancer. We excluded patients with type 
II, poorly differentiated, MI >50% or FIGO stage higher than IA EC.
1. Surgical approach
In both institutions patients underwent surgical staging including total hysterectomy with 
bilateral salpingo-oophorectomy. The lymph nodal status assessment changed over time. 
Given the low-risk features of these patients, up to 2015 the rate of systematic lymph node 
dissection (LND) varied according to the institutional protocols. After 2015 the development 
of sentinel lymph-node mapping (SLN) increased the rate of lymph nodal assessment even 
in low-risk patients. Surgical approach (open abdominal, laparoscopic or robotic-assisted) 
was individualized on the basis of surgeon preference and patient characteristics. We also 
collected data about adjuvant treatment, including patients who underwent external beam 
radiation therapy (EBRT) ± vaginal brachytherapy (VBRT), VBRT only or observation.
2. LVSI definition
In order to determine the LVSI status, pathology reports as well as hematoxylin-and-eosin 
(H&E) stained slides were reviewed by 2 expert pathologists (Z.G.F., A.G.), who were blind 
to clinical data and each other results. LVSI was recorded only if the nests of tumor cells were 
unequivocally lined by endothelial cells.
A 3-tiered system, based on the recommendations by Bosse et al. [4], was used for grading LVSI:
1) Absent: no LVSI
2) Focal: a single focus, consisting of 1–2 vessels involved by neoplasm was recognized 
around the tumor
3) Substantial: diffuse or multifocal LVSI (3 or more involved vessels) was recognized 
around the tumor or massive LVSI was recognized in the myometrium with a spray-like 
growth, regardless of the degree of myometrial invasion
These criteria for interpreting the histological findings were preventively arranged. 
Consensus was reached if both observers agreed. Only few cases with no consensus were 
discussed jointly in a multiheaded microscope until both observers reached an agreement.
3. Data collection
Demographic, surgical, and pathologic data were extracted from the medical reports. 
Demographic data included age and body mass index (BMI). Pathologic data included 
tumor dimensions (greater tumor diameter described at the pathology report), grading, 
and myometrial invasion (MI). Progression free survival (PFS) and overall survival (OS) were 
defined as the time, in months, from the date of diagnosis to the date of recurrence and death 
due to disease or last follow-up, respectively. Recurrences were classified as loco-regional, 
including vaginal and pelvic (pelvic LNs, rectum, bladder) and distant, including abdominal, 
para-aortic LNs and extra-abdominal recurrences (peritoneal carcinomatosis, lung, liver, 
bone). If both pelvic and distant recurrence happened simultaneously, the recurrence was 
categorized as distant.
4. Statistical analysis
Continuous variables were described as mean and standard deviation for normally 
distributed data, or median and interquartile range (IQR). Categorical variables were 
reported as frequencies and percentages. Variables were evaluated for their association 
with distant recurrence based on univariate logistic regression models. Associations were 
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summarized using the odds ratios (ORs), and corresponding 95% confidence intervals 
(CIs) were estimated from the final multivariable logistic regression models. Estimates 
of survival were calculated with the Kaplan-Meier method. Univariable and multivariable 
Cox regression analysis was used to calculate hazard ratio (HR) and 95% CI for factors 
affecting survival. Multivariable analysis included factors who reached a p-value <0.05 
in the univariable analysis. All p-values were 2-sided and a value of <0.05 was considered 
statistically significant.
RESULTS
We enrolled 524 patients who met the inclusion criteria and underwent surgery for 
endometrial cancer in the 2 institutions, Fondazione Policlinco Univesitario A. Gemelli, 
IRCCS (n=503, 96.0%) and A.R.N.A.S. Ospedale Civico di Cristina Benfratelli (n=21, 4.0%), 
between 2003 and 2018. Overall, any degree of LVSI has been found in 10.9% of cases (n=57); 
among these 35 (6.7%) were focal and 22 (4.2%) substantial.
Mean age was 60±10.8 years, mean BMI was 28.7±7.64 kg/m2. The 89.8% of patients (n=468) 
underwent minimally invasive surgery (laparoscopy or robotics). According to the final 
pathology report, the 83.8% of patients (n=439) had MI <50%, and the remaining 16.2% 
(n=85) did not infiltrate the myometrium. Surgical staging included LN evaluation (through 
systematic pelvic and/or aortic LND and or sentinel LN biopsy) in 296 patients (56.5%), while 
228 patients (43.5%) underwent only hysterectomy and bilateral salpingo-oophorectomy. In 
the group of nodal staging, 104 patients (19.8%) underwent sentinel LN only, 58 (11.1%) had 
both SLN and LND and 134 (25.6%) underwent pelvic ± aortic LND.
Table 1 shows clinico-pathological characteristics according to LVSI status in the three tired 
scoring system. We found that patients with substantial LVSI were more likely to have also 
higher frequencies of MI, moderate grade (G2), greater tumor dimensions compared to 
patients with absent and focal LVSI. Moreover, patients with substantial LVSI were more likely 
to undergo adjuvant treatment (1.9% in no LVSI vs. 52.6% in substantial LVSI, p<0.001) and 
to experience distant recurrences (1.8% in no LVSI vs. 22.7% in substantial LVSI, p=0.002). 
The rate of local recurrence was not affected by the presence of LVSI instead.
Substantial LVSI was found to be a negative prognostic factor for both OS and risk of 
recurrence (Fig. 1). With a mean follow up time of 38±32.9 months, we observed a 5-years 
OS of 99.5%, 100%, and 70.6% (p<0.001), and a 5-years DFS of 93.6%, 92.9%, and 56.5% 
(p<0.001) respectively for absent, focal and substantial LVSI.
Adjuvant radiation treatment was not found to be a prognostic factor for both DFS and 
overall survival (OS). In the univariable Cox regression analysis, only substantial LVSI was 
associated to reduced OS (HR=11.7; 95% CI=2.7–50.6; p=0.001) (Table 2).
On multivariable analysis, only substantial LVSI, compared with focal or absent, was 
independently associated with reduced DFS (HR=5.95; 95% CI=2.05–17.65; p=0.001) (Table 3).
Table 4 shows OR for the risk of distant recurrence, unadjusted and adjusted for LVSI score 
and adjuvant treatment. We found that the only independent prognostic factor for distant 
recurrence was the presence of substantial LVSI (adjusted OR=10.65; 95% CI=2–56.7; p=0.006).
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Table 1. Patient characteristics according to LVSI status
Patient characteristic Total Absent LVSI Focal LVSI Substantial LVSI p
No. of patients 524 (100.0) 467 (89.1) 35 (6.7) 22 (4.2)
Mean age (yr) 59.8±11 61.9±9.58 61.1±8.1 0.479
Age (yr) 0.918
<60 257 (49.0) 230 (49.3) 16 (45.7) 11 (50.0)
≥60 267 (51.0) 237 (50.7) 19 (54.3) 11 (50.0)
BMI 0.395
<25 129 (26.2) 116 (26.4) 8 (25.0) 5 (25.0)
≥25 and <35 259 (52.6) 236 (53.6) 13 (40.6) 10 (50.0)
≥35 104 (21.1) 88 (20) 11 (34.4) 5 (25.0)
Surgical approach 0.269
Laparotomy 53 (10.2) 49 (10.6) 4 (11.4) 0
Laparoscopy/robotic 468 (89.8) 415 (89.4) 31 (88.6) 22 (100.0)
LN assessment 0.287
No 228 (43.5) 206 (44.1) 16 (45.7) 6 (27.3)
Yes 296 (56.5) 261 (55.9) 19 (54.3) 16 (72.7)
Tumor dimension (mm) 0.014
≤20 216 (43.2) 202 (45.5) 8 (23.5) 6 (27.3)
>20 284 (56.8) 242 (54.5) 26 (76.5) 16 (72.7)
Grading <0.001
G1 192 (36.6) 191 (40.9) 1 (2.9) 0
G2 332 (63.4) 276 (59.1) 34 (97.1) 22 (100.0)
MI 0.002
No infiltration 85 (16.2) 85 (18.2) 0 0
<50% 439 (83.8) 382 (81.8) 35 (100.0) 22 (100.0)
Adjuvant treatment <0.001
None 482 (93.4) 455 (98.1) 18 (54.5) 9 (47.4)
VBRT only 25 (4.8) 7 (1.5) 13 (39.4) 5 (26.3)
EBRT±VBRT 9 (1.8) 2 (0.4) 2 (6.1) 5 (26.3)
Relapse 0.002
No 482 (94.7) 433 (95.6) 33 (97.1) 16 (72.7)
Local 14 (2.8) 12 (2.6) 1 (2.9) 1 (4.5)
Distant 13 (2.6) 8 (1.8) 0 5 (22.7)
Values are presented as mean±standard deviation or number (%). Missing values are excluded in the analysis.












Absent LVSI: 5 years OS: 99.5%
Focal LVSI: 5 years OS: 100%















Absent LVSI: 5 years DFS: 93.6%
Focal LVSI: 5 years DFS: 92.9%
Diffuse LVSI: 5 years DFS: 56.5%
p<0.001
Fig. 1. Kaplan-Meier estimate of OS and DFS of the 524 patients with low-risk endometrial cancer in relation to the LVSI status. Log rank test was used to test the 
significance and censored patients were indicated by crosses. 
DFS, disease-free survival; LVSI, lymph-vascular space invasion; OS, overall survival.
6/9https://ejgo.org https://doi.org/10.3802/jgo.2021.32.e11
Prognostic role of lymph-vascular space invasion
Table 2. Univariate Cox regression analysis of select covariates for DFS and OS
Characteristics DFS OS
HR (95%CI) p HR (95%CI) p
Age (yr)
<60 1 1
>60 1.12 (0.52–2.39) 0.771 0.5 (0.12–2.01) 0.329
LVSI
LVSI absent 1 1
LVSI focal 0.58 (0.08–4.31) 0.592 -
LVSI substantial 7.95 (3.18–19.86) <0.001 11.9 (2.9–47.6) 0.001
Tumor dimensions (mm)
<20 1 1
>20 0.85 (0.38–1.91) 0.701 0.44 (0.1–1.85) 0.265
LND
No 1 1
Yes 2.62 (1.14–6.03) 0.024 2.1 (0.54–8.8) 0.274
Grading
G1 1 1
G2 3.28 (1.13–9.48) 0.028 1.18 (0.29–4.71) 0.818
Adjuvant treatment
No 1 1
Yes 2.17 (0.75–6.31) 0.153 1.4 (0.18–11.6) 0.724
Missing values are excluded in the analysis.
CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; LND, lymph node dissection; LVSI, lymph-
vascular space invasion; OS, overall survival.
Table 3. Multivariate Cox regression analysis of predictors of recurrence
Variables DFS
HR 95% CI p
LVSI substantial 5.88 2.29–15.11 0.001
G2 2.32 0.76–7.04 0.138
LND 2.16 0.92–5.07 0.075
CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; LND, lymph node dissection; LVSI, lymph-
vascular space invasion.
Table 4. Univariable and multivariable logistic regression analysis of risk factors for distant metastasis among patients at low risk
Characteristics Distant recurrence (n=13) Unadjusted OR (95% CI) p Adjusted OR (95% CI) p
Age (yr)
<60 8 (3.3) 1
>60 5 (1.9) 0.58 (0.19–1.79) 0.340
LVSI
LVSI absent 8 (1.8) 1 1
LVSI focal 0 - -
LVSI Substantial 5 (22.7) 16.3 (4.84–55.29) <0.001 10.65 (2–56.69) 0.006
Tumor dimensions (mm)
<20 4 (1.9) 1
>20 9 (3.3) 1.73 (0.52–5.69) 0.369
LND
No 3 (1.4) 1
Yes 10 (3.4) 2.5 (0.69–9.3) 0.163
Grading
G1 1 (0.5) 1
G2 12 (3.7) 7.01 (0.9–54.4) 0.062
MI
No infiltration 0 1
<50% 13 (3.1) 5.45 (0.32–92.6) 0.141
Adjuvant treatment
No 9 (1.9) 1 1
Yes 4 (9.5) 5.35 (1.57–18.2) 0.007 2.04 (0.34–12.2) 0.435
CI, confidence interval; LND, lymph node dissection; LVSI, lymph-vascular space invasion; MI, myometrial infiltration; OR, odds ratio.
DISCUSSION
Endometrial cancer is the most frequent disease of the genital female tract carrying a 
relatively good prognosis, especially in early-stage of disease. However, the identification of 
risk factors for decreased survival is crucial specifically in those patients in which adjuvant 
treatment is not always recommended.
In this study we focused on the impact of a three-tiered scoring system of LVSI on prognosis 
in patients with low-risk endometrial cancer. We selected patients with well-moderately 
differentiated (G1–G2) endometrial endometrioid cancer, infiltrating less than 50% of the 
myometrium. Consistently with data reported in literature we found that: i) the overall rate 
of LVSI was 10.9% in patients with low-risk EC, among whom 6.7% were focal and 4.2% 
were substantial, ii) substantial LVSI is an independent risk factor for distant recurrences iii) 
substantial LVSI is the strongest predictor of poor prognosis in terms of OS and DFS.
LVSI has been frequently associated to lymph nodal metastasis and several high-risk 
pathologic features resulting consequently in poor prognosis. We specifically analyzed a very 
selected population, with negative LN and no other high-risk pathologic characteristics in 
order to catch as much as possible pure impact of LVSI on prognosis.
The presence of LVSI has been described in literature to be around the 8.9% and 13.5% [5,6] in 
FIGO stage I EC. However, few studies focused specifically its prevalence and prognostic impact 
in low-risk patients. In our study we found that 6.7% of patients had focal LVSI and 4.2% had 
substantial LVSI. Accordingly with our findings, these authors described increased frequencies 
of MI, grade 2 and recurrence rate among patients with LVSI positive. There is a significant 
accordance in literature on the detrimental role of LVSI on prognosis and survival, even in 
early-stage node negative patients [1,5-11]. However, the role of a quantitative scoring system, as 
independent prognostic factors for distant metastasis and OS was not extensively evaluated.
In this study, we found a significantly higher risk of recurrence and death due to disease in 
patients with substantial LVSI. In the multivariate analysis, substantial LVSI was the strongest 
independent factor for recurrence. In the univariate analysis we found a detrimental role of 
LN dissection on prognosis. Since nodal assessment has not been performed in a systematic 
way in all patients, we interpreted this data as due to a higher frequency of MI, greater tumor 
diameter and grade 2 among patients who underwent nodal dissection, justifying in this way 
the poorer prognosis of those patients.
Substantial LVSI was also the strongest independent factor for distant metastasis, despite 
those patients were more likely to receive adjuvant treatment.
In our study, adjuvant treatment was administered to 6.5% of the entire cohort (n=34), with 
an increasing rate in patients with positive LVSI compared to those with no LVSI (1.9% vs. 
45.5% vs. 52.6% respectively for absent, focal or substantial LVSI, p<0.001). Accordingly 
with other authors we did not observe a role of adjuvant radiation on the risk of recurrence 
or deaths [12]. However, confirming the debated role of adjuvant radiotherapy, other authors 
reported the role of adjuvant radiation in the improvement of pelvic recurrence control [4,13].
The distant recurrence strongly suggests the role of hematogenous dissemination of 
the tumor. In a large retrospective analysis of 478 patients with early stage LVSI positive 
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endometrial cancer, authors did not find a prognostic role of adjuvant chemotherapy in low 
grade endometrial cancer with positive LVSI [14]. However, the role of adjuvant treatment in 
this subset of patients is still elusive.
The main limitation of this study is the retrospective nature that could have led to miss 
some confounding factors due to the non-homogeneity of the population (nodal staging 
and adjuvant treatment not standardized). However, this is the study with the largest sample 
size of early-stage low-risk patients, and the only study in the literature aiming to correlate a 
quantitative classification of LVSI to prognosis in this selected subset of patients.
The clinical and therapeutic implications of the extent of LVSI in low-risk EC needs to be 
further investigated, maybe our data suggest a crucial prognostic role of substantial LVSI even 
in patients with low-risk features. Distant metastasis advises a future focus both on molecular 
characterization and optimization of postoperative treatment in these patients. Waiting other 
definitive data on tumor profiling and risk stratification, LVSI and its pathological definition 
should still be considered in tailoring of adjuvant strategies.
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